Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas

A report from the Children's Oncology Group

Kenneth J Cohen, Richard L. Heideman, Tianni Zhou, Emiko J. Holmes, Robert S. Lavey, Eric Bouffet, Ian F. Pollack

Research output: Contribution to journalArticle

Abstract

An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90mg/m2/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m2/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.

Original languageEnglish (US)
Pages (from-to)410-416
Number of pages7
JournalNeuro-Oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

temozolomide
Glioma
Disease-Free Survival
Chemoradiotherapy
Therapeutics
Survival Rate

Keywords

  • Chemoradiotherapy
  • DIPG
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas : A report from the Children's Oncology Group. / Cohen, Kenneth J; Heideman, Richard L.; Zhou, Tianni; Holmes, Emiko J.; Lavey, Robert S.; Bouffet, Eric; Pollack, Ian F.

In: Neuro-Oncology, Vol. 13, No. 4, 04.2011, p. 410-416.

Research output: Contribution to journalArticle

Cohen, Kenneth J ; Heideman, Richard L. ; Zhou, Tianni ; Holmes, Emiko J. ; Lavey, Robert S. ; Bouffet, Eric ; Pollack, Ian F. / Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas : A report from the Children's Oncology Group. In: Neuro-Oncology. 2011 ; Vol. 13, No. 4. pp. 410-416.
@article{2e6341c9f71e4b06a32a4a9383dbc5c4,
title = "Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group",
abstract = "An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90mg/m2/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m2/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9{\%} observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14{\%} ± 4.5{\%}, compared with 21.9{\%} ± 5{\%} for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9{\%}. The mean 1-year OS (± standard deviation) was 40{\%} ± 6.5{\%}, compared with 32{\%} ± 6{\%} for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.",
keywords = "Chemoradiotherapy, DIPG, Temozolomide",
author = "Cohen, {Kenneth J} and Heideman, {Richard L.} and Tianni Zhou and Holmes, {Emiko J.} and Lavey, {Robert S.} and Eric Bouffet and Pollack, {Ian F.}",
year = "2011",
month = "4",
doi = "10.1093/neuonc/noq205",
language = "English (US)",
volume = "13",
pages = "410--416",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas

T2 - A report from the Children's Oncology Group

AU - Cohen, Kenneth J

AU - Heideman, Richard L.

AU - Zhou, Tianni

AU - Holmes, Emiko J.

AU - Lavey, Robert S.

AU - Bouffet, Eric

AU - Pollack, Ian F.

PY - 2011/4

Y1 - 2011/4

N2 - An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90mg/m2/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m2/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.

AB - An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90mg/m2/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m2/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.

KW - Chemoradiotherapy

KW - DIPG

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=79955760460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955760460&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq205

DO - 10.1093/neuonc/noq205

M3 - Article

VL - 13

SP - 410

EP - 416

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -